股价提前异动！亚辉龙跨界“脑机接口” ，引来上交所三连问

Core Viewpoint - The company Aihuilong (688575.SH) is entering the brain-computer interface (BCI) sector through a strategic cooperation agreement with Shenzhen Brain Machine Starlink Technology Co., Ltd, aiming to enhance diagnostic technology for central nervous system diseases and expand market reach [1][4]. Group 1: Strategic Cooperation - Aihuilong signed a strategic cooperation framework agreement with Brain Machine Starlink to integrate BCI technology with clinical and market resources [1]. - The company committed to leveraging its influence to enhance Brain Machine Starlink's financing and governance capabilities [2]. - The cooperation aims to develop BCI-related products and promote market expansion, although it has raised questions regarding the feasibility and synergy of the collaboration [2][12]. Group 2: Financial Performance - Aihuilong's revenue for the first three quarters of 2025 was 1.287 billion yuan, a year-on-year decline of 7.69%, with net profit dropping 72.36% to 60.42 million yuan [4]. - The company's stock price fell by 8.83% over the past year, with its market capitalization dropping to around 9 billion yuan [4]. - Despite the announcement of the BCI cooperation, the company's financial outlook remains uncertain, with no immediate impact on performance expected [10]. Group 3: Market Reaction - Following the announcement, Aihuilong's stock price initially rose by 3% but later experienced a decline [11]. - The Shanghai Stock Exchange issued an inquiry regarding the cooperation, questioning potential insider trading and requiring additional disclosures about the partnership [3][12]. - The BCI sector has seen a surge in interest, with related stocks experiencing significant gains, influenced by announcements from other companies in the field [10].